Healthcare/Biotech
Indian pharma has little reason to fear Trump
US tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially cause shortages. Indian firms operate on low margins, making tariff absorption difficult. Recent US manufacturing experiences offer little incentive for relocation. Targeted incentives offer a more direct approach to supply chain resilience.
- Udan vs Udaan: Delhi court restrains pharmaceutical firm from using 'Udaan' mark
- Govt tightens rules on combinations containing 2 chemical compounds for young children
- Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection
- Medical devices industry needs to focus more on local value addition: Pharma Secy
- Delhi High Court rules in favour of Dr Reddy's Labs in trademark row with Razenta
- Danish firm Novonesis to roll out ₹3,000 crore Maharashtra investment over 2-3 years
- Mankind Pharma inks in-licensing pact with China's Chongqing Chenan Biopharmaceutical
- Lord's Mark Industries outlines strategic expansion across global healthcare, advanced diagnostics & oncology; targets ₹1,550 Crore revenue in FY2027
- Lupin arm to commercialise YUVEZZI eye drop across key European markets
- Moderna, Merck breakthrough could usher in wave of cancer vaccines
- Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health Sciences
- Lord’s Mark Industries announces license for biomescan analytics platform
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health Sciences
Lord’s Mark Industries announces license for biomescan analytics platform
Apollo Hospitals extends services to all seven days of week
Manipal Health Enterprises to acquire Kinder Women's Hospital in Bengaluru
Healthcare delivery capital-intensive, hospital tariffs only tip of iceberg: NATHEALTH
Biotech
Danish firm Novonesis to roll out ₹3,000 crore Maharashtra investment over 2-3 years- Mankind Pharma inks in-licensing pact with China's Chongqing Chenan Biopharmaceutical
- Lord’s Mark Industries announces license for biomescan analytics platform
- Thermo Fisher finds India the perfect lab; lab equipment maker steps up investments as drug companies focus on innovation
- NITI Aayog roadmap targets USD 691 bn bioeconomy by 2035; Jitendra Singh says India ready to lead biotech revolution
Healthcare
Lord's Mark Industries outlines strategic expansion across global healthcare, advanced diagnostics & oncology; targets ₹1,550 Crore revenue in FY2027- Moderna, Merck breakthrough could usher in wave of cancer vaccines
- Apollo Hospitals extends services to all seven days of week
- Manipal Health Enterprises to acquire Kinder Women's Hospital in Bengaluru
- Healthcare delivery capital-intensive, hospital tariffs only tip of iceberg: NATHEALTH
Pharmaceuticals
Govt tightens rules on combinations containing 2 chemical compounds for young children
Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection
Medical devices industry needs to focus more on local value addition: Pharma Secy
Delhi High Court rules in favour of Dr Reddy's Labs in trademark row with Razenta
Lupin arm to commercialise YUVEZZI eye drop across key European markets
Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health Sciences
Must Watch
